Immortal Time Bias or Sorafenib Effect in Elderly Patients With HCC?

Hepatology - United States
doi 10.1002/hep.29250
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Response to Letter, ‘Immortal Time Bias in Retrospective Analysis’

Blood Cancer Journal
OncologyHematology
2015English

Inhaled Steroids and Mortality in COPD: Bias From Unaccounted Immortal Time

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2004English

Table 1: Baseline Characteristics of Elderly Patients With HCC.

English

Thyroid Dysfunction in Patients Treated With Sunitinib or Sorafenib

Clinical Genitourinary Cancer
OncologyUrology
2012English

Hypothyroidism Side Effect in Patients Treated With Sunitinib or Sorafenib: Clinical and Structural Analyses

PLoS ONE
Multidisciplinary
2016English

Immortal Time Bias: Comment on the Article by Gwinnutt Et Al

Arthritis and Rheumatology
RheumatologyAllergyImmunology
2017English

Changing TACTICS in Intermediate HCC: TACE Plus Sorafenib

Gut
Gastroenterology
2020English

Sorafenib or Placebo Plus TACE With Doxorubicin-Eluting Beads for Intermediate Stage HCC: The SPACE Trial

Journal of Hepatology
Hepatology
2016English

HCC Risk in Patients With HBV-related Cirrhosis Receiving NA Therapy: Is HCC Prevented or Delayed?

Hepatology
MedicineHepatology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy